Rein Therapeutics, Inc. 8-K Filing
Ticker: RNTX · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Rein Therapeutics, Inc. (RNTX) |
| Form Type | 8-K |
| Filed Date | Nov 3, 2025 |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Rein Therapeutics, Inc. (ticker: RNTX) to the SEC on Nov 3, 2025.
How long is this filing?
Rein Therapeutics, Inc.'s 8-K filing is 1 pages with approximately 431 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 431 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2025-11-03 07:45:11
Filing Documents
- d47241d8k.htm (8-K) — 23KB
- d47241dex991.htm (EX-99.1) — 12KB
- 0001193125-25-261706.txt ( ) — 154KB
- rntx-20251103.xsd (EX-101.SCH) — 3KB
- rntx-20251103_lab.xml (EX-101.LAB) — 18KB
- rntx-20251103_pre.xml (EX-101.PRE) — 11KB
- d47241d8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On November 3, 2025, Rein Therapeutics, Inc. ("Company") issued a press release concerning FDA clearance for the Company to resume its U.S. Phase 2 Trial of LTI-03 in idiopathic pulmonary fibrosis. A copy of the press release is attached as Exhibit 99.1 hereto. Item9.01 Financial Statements and Exhibits (d) Exhibits The following exhibits are filed with this report: Exhibit 99.1 The Company's press release dated November 3, 2025 Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REIN THERAPEUTICS, INC. Dated: November 3, 2025 /s/ Brian Windsor Brian Windsor, Ph.D., President and Chief Executive Officer